Sorry - the earlier post was incomplete - here it is again
gorsen - the AGM was dissapointing for reasons which are not directly to do with Quintiles - rather because there was a lack of detail - which I am sure we will see in days to come. The deal could have been signed as late as Friday with some factors still being worked upon before a press release (happens all the time when you are dealing with a huge Unlisted company).
Your statement "few hundred thousand in revenue for calendar 2012" - I am not so sure how you came to that figure and frankly find it ridiculous.
-- World Wound Care market - Size $14B
-- VitroGro Launch 2Q 2012 (i.e. within 6 months) in UK, Germany, Italy and some others - And ONLY UK, Germany & Italy have 42% of the World Market Size = approx $5.5 Billion
With a NETT revenue at about 20-25% (royalty + manufacturing or even a split between Quintiles and TIS) even a TINY LAUGHABLE PESSIMISTIC WEIRD 1% of this market - $55 million would put approx $10 million into the pockets of TIS.
Are you trying to contemplate that ONLY $1 or 2 Million sale in a $5.5 Billion Market over 6 months ?? - Come on mate - I dont believe a serious Pharma would be interested in Partnering with someone who will earn loose change (and Quintiles are very serious if you do some research on them).
My thoughts only - DYOR
Add to My Watchlist
What is My Watchlist?